艾拉莫德与羟氯喹治疗干燥综合征的疗效及安全性

Efficacy and Safety of Iremod and Hydroxychloroquine in the Treatment of Sjogren's Syndrome

目的观察艾拉莫德与羟氯喹在干燥综合征患者中的治疗效果以及安全性。方法以60例干燥综合征患者为研究对象,采用随机双盲法分为观察组与对照组,各30例。观察组予以艾拉莫德治疗,对照组予以羟氯喹治疗。对治疗效果、不良反应发生率等指标进行比较。结果观察组患者总有效率93.33%,显著高于对照组(80.00%,P<0.05)。观察组患者不良反应发生率13.33%,显著低于对照组(30.00%,P<0.05)。观察组患者治疗后免疫球蛋白G(IgG)、血沉(ESR)水平为均低于对照组,血小板(PLT)高于对照组(P<0.05)。结论艾拉莫德在干燥综合征患者中的干预效果更为理想,安全性更高。

Objective To explore the efficacy and safety of Iremod and hydroxychloroquine in the treatment of Sjogren's syndrome.Methods Sixty patients with Sjogren's syndrome were divided into observation group and control group by random double-blind method,30 cases each.The control group was treated with hydroxychloroquine and the observation group was treated with Iremod.The therapeutic effect and the incidence of adverse reactions of the patients were compared.Results The efficiency of the observation group was 93.33%,higher than that of the control group(80.00%,P<0.05).The incidence of adverse reactions in the observation group was 13.33%,which was lower than that in the control group(30.00%,P<0.05).After treatment,the levels of IgG and ESR in the observation group were lower than those in the control group,and PLT was higher than that in the control group(P<0.05).Conclusion Iremod is more effective and safe in the treatment of Sjogren's syndrome.